Rita Nanda

3.7k total citations · 1 hit paper
22 papers, 1.5k citations indexed

About

Rita Nanda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Rita Nanda has authored 22 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Rita Nanda's work include Cancer Immunotherapy and Biomarkers (8 papers), Advanced Breast Cancer Therapies (7 papers) and HER2/EGFR in Cancer Research (6 papers). Rita Nanda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Advanced Breast Cancer Therapies (7 papers) and HER2/EGFR in Cancer Research (6 papers). Rita Nanda collaborates with scholars based in United States, Spain and France. Rita Nanda's co-authors include Ravit Geva, Vassiliki Karantza, Laurence Buisseret, Gursel Aktan, Shilpa Gupta, Elizabeth Claire Dees, Raanan Berger, Jonathan D. Cheng, Laura Q.M. Chow and Kumudu Pathiraja and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Rita Nanda

18 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

2016 1.1k citations Rita Nanda, Laura Q.M. Chow et al. Journal of Clinical Oncology profile →

Peers

Rita Nanda

ONCOL

IMMUN

PRM

Alexios Matikas Sweden

Luisa Carbognin Italy

Christine Lagorce France

Ioannis Zerdes Sweden

Qijia Xuan China

Josephine A. Ratikan United States

Angela Listì Italy

Susumu Inamoto Japan

Rilan Bai China

Nigel C. Bird United Kingdom

Alexios Matikas Sweden

Rita Nanda

929 ×0.8

ONCOL

276 ×0.5

IMMUN

370 ×0.9

PRM

413 ×1.3

395 ×1.6

Citations per year, relative to Rita Nanda Rita Nanda (= 1×) peers Alexios Matikas

Countries citing papers authored by Rita Nanda

Since Specialization

Citations

This map shows the geographic impact of Rita Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nanda more than expected).

Fields of papers citing papers by Rita Nanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nanda. The network helps show where Rita Nanda may publish in the future.

Co-authorship network of co-authors of Rita Nanda

This figure shows the co-authorship network connecting the top 25 collaborators of Rita Nanda. A scholar is included among the top collaborators of Rita Nanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rita Nanda. Rita Nanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Nan, et al.. (2025). Abstract GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer. Clinical Cancer Research. 31(12_Supplement). GS3–3. 2 indexed citations

Parsons, Heather A., Leslie Cope, Jenna VanLiere Canzoniero, et al.. (2025). Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial).. Journal of Clinical Oncology. 43(16_suppl). 1009–1009. 4 indexed citations

Nanda, Rita, Ronald Cohen, Zoe Quandt, et al.. (2024). Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.. Journal of Clinical Oncology. 42(16_suppl). 584–584.

Hurvitz, Sara A., Anne F. Schott, X. Cynthia, et al.. (2024). Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Cancer Research. 84(9_Supplement). PO3–5. 6 indexed citations

Pohlmann, Paula R., David A. Potter, Nan Chen, et al.. (2024). PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1).. Journal of Clinical Oncology. 42(16_suppl). e12641–e12641. 1 indexed citations

Chien, A. Jo, Hatem Soliman, Judy C. Boughey, et al.. (2021). Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.. Journal of Clinical Oncology. 39(15_suppl). 508–508. 14 indexed citations

Garrido-Castro, Ana C., Tanya E. Keenan, Tianyu Li, et al.. (2021). Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology. 39(15_suppl). TPS1102–TPS1102. 6 indexed citations

Vidula, Neelima, Rita Nanda, Kathy D. Miller, et al.. (2021). Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.. Journal of Clinical Oncology. 39(15_suppl). TPS1111–TPS1111.

Stringer-Reasor, Erica, Yufeng Li, Jennifer M. Specht, et al.. (2021). Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).. Journal of Clinical Oncology. 39(15_suppl). TPS1098–TPS1098. 3 indexed citations

10.

Garrido-Castro, Ana C., Tanya E. Keenan, Tianyu Li, et al.. (2021). Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). TPS1106–TPS1106. 18 indexed citations

11.

Howard, Frederick M., et al.. (2021). Independent validation of simbiosys tumorscope to predict response to neoadjuvant chemotherapy (NACT) in early breast cancer (EBC).. Journal of Clinical Oncology. 39(15_suppl). 582–582. 4 indexed citations

12.

Reizine, Natalie, Everett E. Vokes, Ping Liu, et al.. (2020). Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Therapeutic Advances in Medical Oncology. 12. 3863589158–3863589158. 15 indexed citations

13.

Nanda, Rita, et al.. (2018). Immune Checkpoint Blockade for Breast Cancer. Cancer treatment and research. 173. 155–165. 73 indexed citations

14.

Danahey, Keith, Rita Nanda, Blasé N. Polite, et al.. (2018). Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 124(14). 3052–3065. 15 indexed citations

15.

Danahey, Keith, Sang Mee Lee, Linda Patrick‐Miller, et al.. (2018). Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenetics and Genomics. 29(2). 31–38. 24 indexed citations

16.

Schmid, Peter, Cristina Cruz, Fadi S. Braiteh, et al.. (2017). Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Research. 77(13_Supplement). 2986–2986. 92 indexed citations

17.

Knoebel, Randall W., et al.. (2017). Retrospective chart evaluation of hypercalcemia management in oncology patients at the University of Chicago Medical Center. Journal of Oncology Pharmacy Practice. 25(2). 317–325.

18.

Nanda, Rita, et al.. (2016). Concepts and targets in triple-negative breast cancer: recent results and clinical implications. Therapeutic Advances in Medical Oncology. 8(5). 351–359. 25 indexed citations

19.

Nanda, Rita, Laura Q.M. Chow, Elizabeth Claire Dees, et al.. (2016). Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology. 34(21). 2460–2467. 1112 indexed citations breakdown →

20.

Cynthia, X., Vera J. Suman, Matthew P. Goetz, et al.. (2013). A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 139(1). 145–153. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact